Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many safety-related statements are supported (liver dysfunction, need for liver function tests, and symptoms such as jaundice/dark urine/pale stools). However, several efficacy/indication statements are overbroad relative to the provided label excerpt, and several quantitative/rarity estimates are not supported. Some interaction and monitoring details are also missing or imprecise compared with the label.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is used to lower cholesterol levels.
Label indicates LIPITOR is used as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C (Hyperlipidemia).
Lipitor belongs to the class of medications called statins.
Label uses/defines statins as HMG-CoA reductase inhibitors (Mechanism of Action; Warnings and Precautions).
Statins work by inhibiting the production of cholesterol in the liver.
Label mechanism: selective competitive inhibitor of HMG-CoA reductase; a precursor of sterols including cholesterol.
Lipitor has been associated with an increased risk of liver damage.
Label: statins have been associated with biochemical abnormalities of liver function; persistent transaminase elevations occurred.
Regular blood tests can help detect changes in liver function while taking Lipitor.
Label: perform liver function tests prior to and at 12 weeks following initiation and after any elevation of dose, and periodically thereafter.
Liver function tests can help identify abnormalities in liver function while taking Lipitor.
Label: biochemical abnormalities of liver function; recommendation for liver function testing with thresholds for action.
Unsupported Statements
Lipitor (atorvastatin) is used to prevent heart disease.
The provided label excerpt specifies reducing risk of myocardial infarction, stroke, revascularization/angina, and other cardiovascular outcomes, but does not explicitly state 'prevent heart disease' as phrased.
Jaundice (yellowing of the skin and eyes) may indicate liver problems while taking Lipitor.
The provided label excerpt includes recommendations for liver function tests and transaminase abnormalities, but does not explicitly list jaundice as a symptom of liver dysfunction in the supplied sections.
Dark urine may indicate liver problems while taking Lipitor.
Not explicitly supported in the supplied label excerpt.
Pale stools (change in stool color) may indicate liver problems while taking Lipitor.
Not explicitly supported in the supplied label excerpt.
Loss of appetite (decrease in appetite) may indicate liver problems while taking Lipitor.
Not explicitly supported in the supplied label excerpt.
Nausea and vomiting may be indicative of liver problems while taking Lipitor.
Not explicitly supported in the supplied label excerpt.
The increased risk of liver damage from Lipitor includes liver failure.
Postmarketing adverse reactions list includes 'hepatic failure', but the supplied label excerpt does not connect 'increased risk of liver damage' to 'liver failure' as a causal risk statement.
The increased risk of liver damage from Lipitor includes liver transplant.
Not explicitly supported in the provided label excerpt.
The risk of liver damage from Lipitor is relatively rare.
The excerpt provides a specific incidence for persistent transaminase elevations (0.7%) but does not characterize overall 'liver damage' as 'relatively rare' or use that phrasing.
The risk of liver damage from Lipitor occurs in less than 1% of patients taking the medication.
The excerpt provides 0.7% for persistent transaminase elevations but does not explicitly equate that to 'liver damage' risk (<1%) overall.
Older adults may be at higher risk of liver damage from Lipitor.
The supplied label excerpt does not provide a statement linking older adults to increased liver damage risk.
People with pre-existing liver disease may be at higher risk of liver damage from Lipitor.
The excerpt includes contraindication for active liver disease, but does not state that people with pre-existing liver disease have higher risk of liver damage (beyond the contraindication).
People taking other medications that can cause liver damage may be at higher risk of liver damage from Lipitor.
The provided label excerpt does not state this interaction/risk relationship.
Monitoring for symptoms such as jaundice, dark urine, and pale stools can help identify liver problems early while taking Lipitor.
Symptom-based monitoring for these specific symptoms is not supported by the supplied label excerpt (which emphasizes liver function tests).
If liver-related side effects are experienced while taking Lipitor, medical attention should be sought immediately.
The excerpt provides testing and dose reduction/withdrawal recommendations but does not include an instruction to seek immediate medical attention for these symptoms.
A doctor may adjust the dosage of Lipitor to minimize the risk of liver damage.
The label excerpt specifies reduction of dose or withdrawal if ALT/AST increases persist; however the claim is not stated with the label’s specific threshold-based recommendation.
A doctor may switch to a different medication that is less likely to cause liver damage.
The excerpt recommends dose reduction or withdrawal, but does not state switching to a different medication.
A doctor may monitor liver function regularly to ensure it is not being damaged by the medication.
Label supports periodic liver function tests, but not the phrasing 'to ensure it is not being damaged' (still broadly aligned, yet not explicitly stated as such in provided text).
Contradictions
Low
AI Statement
The increased risk of liver damage from Lipitor includes liver transplant.
Label Reference
No such statement is present in the provided label excerpt.
Important Omissions
Dose adjustment/monitoring specifics for liver dysfunction: perform liver function tests prior to and at 12 weeks after initiation and after dose increases; if ALT/AST >3 times ULN persists, reduce dose or withdraw.
Importance:
Moderate
The label excerpt emphasizes contraindication in pregnancy and active liver disease; the evaluated statements did not address contraindications.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements about liver-related symptom monitoring (jaundice/dark urine/pale stools, appetite loss, nausea/vomiting) and quantitative rarity (<1%, relatively rare), plus 'liver transplant' and older adult/pre-existing liver disease risk are not supported by the supplied label excerpt. While the core concept of liver dysfunction monitoring via liver function tests is supported, the unsupported symptom/risk precision could mislead interpretation of when/how to monitor.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Overbroad/unsupported claims (heart disease prevention phrasing; liver-related symptom list; quantitative rarity; liver transplant; risk stratification for older adults and pre-existing liver disease) relative to the provided label excerpt.
Suggested Improvement
Rephrase indication to match label outcomes (MI, stroke, revascularization/angina) and remove unsupported symptom-based 'liver problems' monitoring and unsupported quantitative/risk-statements. Emphasize label-supported liver function testing schedule and the specific ALT/AST (>3×ULN) threshold for dose reduction/withdrawal.